Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Urogen Pharma Ltd
(NQ:
URGN
)
12.48
+0.57 (+4.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Urogen Pharma Ltd
< Previous
1
2
3
4
5
6
7
Next >
79 Biggest Movers From Yesterday
June 08, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...
Via
Benzinga
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Recap: UroGen Pharma Q4 Earnings
March 21, 2022
UroGen Pharma (NASDAQ:URGN) reported its Q4 earnings results on Monday, March 21, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
UroGen Pharma Earnings Preview
March 18, 2022
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
May 25, 2022
On Wednesday, 215 companies set new 52-week lows.
Via
Benzinga
UroGen Pharma to Present at Upcoming Investor Conferences
May 18, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 16, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 10, 2022
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
May 16, 2022
On Monday, 198 companies reached new 52-week lows.
Via
Benzinga
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 13, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Outlook For UroGen Pharma
May 09, 2022
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma...
Via
Benzinga
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
March 29, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For May 10, 2022
May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Via
Benzinga
UroGen Pharma's Return On Capital Employed Overview
March 22, 2022
According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a...
Via
Benzinga
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
March 21, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 21, 2022
March 21, 2022
Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million. •...
Via
Benzinga
How To Attend UroGen Pharma Q4 2021 Earnings Conference Call
March 18, 2022
UroGen Pharma (NASDAQ:URGN) will host a conference call at 10:00 AM ET on March 21, 2022, to discuss Q4 2021 earnings results. How to Attend UroGen Pharma (URGN) Conference Call...
Via
Benzinga
Earnings Outlook For UroGen Pharma
March 18, 2022
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
UroGen Pharma Q4 2021 Earnings Conference Call On March 21, 2022 At 10:00 AM ET
March 17, 2022
UroGen Pharma (NASDAQ:URGN) will host a conference call at 10:00 AM ET on March 21, 2022, to discuss Q4 2021 earnings results. How to Attend UroGen Pharma (URGN) Conference Call...
Via
Benzinga
Earnings Outlook For UroGen Pharma
March 09, 2022
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
February 28, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
February 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
88 Biggest Movers From Yesterday
March 09, 2022
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) climbed 203.3% to settle at $1.00 on Tuesday. Hycroft recently reported preliminary FY21 operating results. Kala...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 22, 2022
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...
Via
Benzinga
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
February 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.